Chair
Robert J. Motzer, MD
Medical Oncologist
Genitourinary Division
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert A. Figlin, MD
Chair, Medical Oncology and Experimental Therapeutics
Acting Cancer Center Director
City of Hope
Duarte, California

Program Overview
Improving patient care by incorporating evidence-based research on targeted therapies into the management of patients with metastatic renal cell carcinoma (RCC) provides a challenge for the busy oncologist. Continuing education activities designed to translate clinical trial data into therapeutic strategies can provide much needed guidance.

The role of approved and emerging agents for the management of RCC continues to evolve. Approval of 3 targeted therapies for use as single agents represents significant progress in improved patient care. Emerging data on the sequential use of single-agent therapy and potential identification of indicators for responsiveness to therapy continue to challenge the oncologist’s comfort with identifying patients most likely to respond. In addition, it has become apparent that combining targeted therapies that inhibit the same or distinct pathways, as well as using targeted therapies to enhance cytokine therapy, shows great promise. Finally, there are opportunities for the oncologist to improve patient outcomes by referral to numerous ongoing clinical trials.

Intended Audience
Community oncologists treating patients with advanced renal cell carcinoma.

Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Veritas Institute for Medical Education, Inc. designates each educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsorship and Support
Sponsored by Veritas Institute for Medical Education, Inc.
Supported by educational grants from Novartis Oncology and Pfizer Inc.

Unlabeled Use Disclosure Statement
The relevant financial relationships of those persons in a position to control the content of this CME activity will be disclosed prior to the start of the educational activity. Participants are advised that this CME activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with renal cell carcinoma.

Disclaimer
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Veritas Institute for Medical Education, Inc., Novartis Oncology, or Pfizer Inc. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

Copyright © 2008 Veritas Institute for Medical Education, Inc. Terms and Privacy Policy. All rights reserved.

Telesymposium 1: Evaluation and First-Line Treatment of the Patient With Clear Cell mRCC
Learning Objectives

1. You will be able to assess the role and efficacy of approved first-line therapies in the treatment of RCC with clear cell histology.
2. You will be able to describe prognostic variables in patients with RCC and to correlate patient outcomes based on stratified risk groups.

Telesymposium 2: The Second-Line Conundrum: Strategies for Handling Disease Progression
Learning Objectives

1. You will be able to assess the role and efficacy of second-line therapies in the treatment of RCC with clear cell histology.
2. You will be able to describe the clinical parameters that influence therapeutic selection for managing patients with disease progression.

Telesymposium 3: Science on the Move: Clinical Trials to Watch
Learning Objectives

1. You will be better able to assess the role of emerging therapeutic agents for the treatment of metastatic renal cell carcinoma.
2. You will be able to appraise the emerging clinical data on biological therapies for the treatment of RCC in order to be better able to refer your patients to appropriate clinical trials.